SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-009749
Filing Date
2020-08-07
Accepted
2020-08-06 19:00:35
Documents
78
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q clvs-20200630x10q.htm   iXBRL 10-Q 2316611
2 EX-10.4 clvs-20200630xex10d4.htm EX-10.4 160096
3 EX-31.1 clvs-20200630xex31d1.htm EX-31.1 15827
4 EX-31.2 clvs-20200630xex31d2.htm EX-31.2 16020
5 EX-32.1 clvs-20200630xex32d1.htm EX-32.1 6441
6 EX-32.2 clvs-20200630xex32d2.htm EX-32.2 6521
  Complete submission text file 0001558370-20-009749.txt   9219885

Data Files

Seq Description Document Type Size
7 EX-101.SCH clvs-20200630.xsd EX-101.SCH 57135
8 EX-101.CAL clvs-20200630_cal.xml EX-101.CAL 79360
9 EX-101.DEF clvs-20200630_def.xml EX-101.DEF 169273
10 EX-101.LAB clvs-20200630_lab.xml EX-101.LAB 588322
11 EX-101.PRE clvs-20200630_pre.xml EX-101.PRE 383031
12 EXTRACTED XBRL INSTANCE DOCUMENT clvs-20200630x10q_htm.xml XML 1714760
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35347 | Film No.: 201083314
SIC: 2834 Pharmaceutical Preparations